These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 3575388)

  • 1. [Improvement of the solubility behavior of problem drugs. 9. In vitro absorption studies using melting solidification products of iomeglamic acid].
    Fahr F; Neubert R; Fürst W; Kala H; Masthoff F
    Pharmazie; 1986 Dec; 41(12):855-6. PubMed ID: 3575388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Improvement of the solubility behavior of problem drugs. 20. The effect of pharmaceutical excipients on the wetability of iomeglamic acid].
    Fahr F; Zessin G; Kala H; Fries G
    Pharmazie; 1989 Aug; 44(8):576-7. PubMed ID: 2594830
    [No Abstract]   [Full Text] [Related]  

  • 3. [The improvement of solubility behavior of problem drugs. 7. Iomeglamic acid-mannitol-melting viscosity products].
    Fahr F; Kala H; Pollandt P; Zessin G
    Pharmazie; 1985 Oct; 40(10):733-4. PubMed ID: 3936061
    [No Abstract]   [Full Text] [Related]  

  • 4. [The improvement of solubility behavior of problem drugs. 2. Solubility behavior of slow dissolving products of iomeglamic acid and succinic acid].
    Fahr F; Kala H; Scharrenweber F
    Pharmazie; 1985 Jan; 40(1):60-1. PubMed ID: 3991791
    [No Abstract]   [Full Text] [Related]  

  • 5. [Improvement of the dissolution behavior of problem drugs. 3. X-ray diffraction measurement of iomeglamic acid/succinic acid solid dispersions].
    Fahr F; Kala H; Pollandt P
    Pharmazie; 1985 Feb; 40(2):127-8. PubMed ID: 4001148
    [No Abstract]   [Full Text] [Related]  

  • 6. [Improvement of the solubility of problem drugs. 1. Production of iomeglamic acid fused and solidified products].
    Fahr F; Kala H; Pollandt P; Wenzel U; Masthoff F
    Pharmazie; 1985 Jun; 40(6):408-9. PubMed ID: 4034650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Improvement of the solubility of problem drugs. 17. Processing of iomeglamic acid/methylcellulose coprecipitates in tablets].
    Fahr F; Kala H; Hückel T; Fries G
    Pharmazie; 1988 Mar; 43(3):216. PubMed ID: 3380870
    [No Abstract]   [Full Text] [Related]  

  • 8. [Improvement of the solubility of problem drugs. 18. Iomeglamic acid-PVA effervescent powder].
    Fahr F; Kala H; Fries G; Helbig G
    Pharmazie; 1988 Mar; 43(3):217. PubMed ID: 3380871
    [No Abstract]   [Full Text] [Related]  

  • 9. [Improvement of the dissolution behavior of problem drugs. 11. DTA iomeglamic-PVP 25 copreciptates].
    Fahr F; Kala H; Masthoff F; Fries G
    Pharmazie; 1986 Jul; 41(7):517. PubMed ID: 3774866
    [No Abstract]   [Full Text] [Related]  

  • 10. [Improvement of the solubility of problem drugs. 15. X-ray diffraction of iomeglamic acid-methylcellulose (MH 300)-PEG 6000-coprecipitate].
    Fahr F; Kala H; Pollandt P; Hückel T; Fries G
    Pharmazie; 1987 Aug; 42(8):554. PubMed ID: 3432342
    [No Abstract]   [Full Text] [Related]  

  • 11. [Improvement of the solubility of problem drugs. 15. Alteration of iomeglamic acid-methylcellulose (MH 300)-PEG 6000 coprecipitates].
    Fahr F; Kala H; Pollandt P; Fries G; Hückel T
    Pharmazie; 1987 Aug; 42(8):552-3. PubMed ID: 3432340
    [No Abstract]   [Full Text] [Related]  

  • 12. [Improvement of the dissolution behavior of problem drugs. 4. Differential thermal analysis of iomeglamic acid-succinic acid embedding].
    Fahr F; Kala H; Masthoff F
    Pharmazie; 1985 Apr; 40(4):270-1. PubMed ID: 4011664
    [No Abstract]   [Full Text] [Related]  

  • 13. Enhanced dissolution of ibuprofen using solid dispersion with poloxamer 407.
    Newa M; Bhandari KH; Oh DH; Kim YR; Sung JH; Kim JO; Woo JS; Choi HG; Yong CS
    Arch Pharm Res; 2008 Nov; 31(11):1497-507. PubMed ID: 19023548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of iomeglamic acid (Falignost)].
    Pfeifer S; Schäffner J; Bornschein I
    Pharmazie; 1972 Jun; 27(6):396-403. PubMed ID: 5082266
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
    Prabhu S; Ortega M; Ma C
    Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physicochemical properties of water and its effect on drug delivery. A commentary.
    Loftsson T; Brewster ME
    Int J Pharm; 2008 Apr; 354(1-2):248-54. PubMed ID: 17920796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption-excipient-pH classification gradient maps: sparingly soluble drugs and the pH partition hypothesis.
    Avdeef A; Kansy M; Bendels S; Tsinman K
    Eur J Pharm Sci; 2008 Jan; 33(1):29-41. PubMed ID: 17983735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers.
    Yang W; Tam J; Miller DA; Zhou J; McConville JT; Johnston KP; Williams RO
    Int J Pharm; 2008 Sep; 361(1-2):177-88. PubMed ID: 18556158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of the phase behavior of polyethylene glycol 6000-itraconazole solid dispersions using DSC.
    Wang X; Michoel A; Van den Mooter G
    Int J Pharm; 2004 Mar; 272(1-2):181-7. PubMed ID: 15019081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relating solubility data of parabens in liquid PEG 400 to the behaviour of PEG 4000-parabens solid dispersions.
    Unga J; Tajarobi F; Norder O; Frenning G; Larsson A
    Eur J Pharm Biopharm; 2009 Oct; 73(2):260-8. PubMed ID: 19508891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.